Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Targeting novel lipid pathways for treatment of cardiovascular disease (ATHERO-FLUX)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,Finland,Germany,Denmark,Greece,Finland,France,Sweden,Denmark,Israel,Italy
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-09-01
End date: 2019-02-28
Duration (months): 66.0
Total project cost (EUR): 7860933.33
EU funding (EUR): 5987700.0
Participants: 12
Project status: CLOSED

Lipid lowering has significantly reduced cardiovascular disease (CVD) mortality in EU. However, the aim to abolish CVD in EU is far from achieved and attempts to improve on the benefits of statins with new agents have not yet delivered new therapeutics. The Consortium Athero-Flux builds on FP7-generated large-scale lipidomics data showing that specific sphingolipids and in particular distinct ceramides with specific acyl chain lengths are better predictors of CV outcome than traditional risk factors such as low-density lipoprotein-cholesterol. Sphingolipids are implicated in significant biological activities including cell survival, inflammation, and metabolic diseases. Moreover, their levels in metabolic diseases are modulated by previously unrecognized factors such as the gut microflora. Thus, we hypothesize that by controlling sphingolipid metabolism a better primary and secondary prevention of CVD events than with statins alone can be achieved. Athero-Flux builds on cutting-edge SME-led biotechnological tools including: a) high-throughput lipidomic platforms that allow the study of kinetics of lipid metabolism at the molecular lipid level including the new stable isotope labelling technique (Flux); b) whole genome RNA interference screening tools that will allow to identify the regulators of the production of ceramides and the mediators of their biological effect; c) unique locked nucleotide antagonist platforms that have been successfully used clinically in more that 300 patients worldwide. Moreover, it involves Academic partners with top expertise in atherosclerosis, sphingolipid metabolism, and gut microflora to validate targets in the ceramide metabolism. The identification and the validation of the best targets to abate ceramide metabolism though a combination of SME-based leading technology and academia modeling has a strong potential for development of new lipid lowering therapeutics to abate previously unrecognized risk factors for CVD.

Keywords: lipids,lipidomics,rna interference,signalling,inflammation,atherosclerosis,cardiovascular disease,coronary artery disease,oligonucleotides
Immunostimulatory Agonist antibodies for Cancer Therapy (IACT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,United Kingdom,Spain,Italy,Germany,Germany,Sweden,Spain
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-11-01
End date: 2017-10-31
Duration (months): 48.0
Total project cost (EUR): 8227907.6
EU funding (EUR): 5995747.0
Participants: 10
Project status: CLOSED

This concerted action aims at providing new treatment options for cancer patients through boosting innovative drug development by European academia and industry. A wealth of preclinical data shows that the therapeutic impact of cytotoxic regimens is enhanced by simultaneous application of drugs that strengthen the immune system. The recent FDA-approval of Ipilimumab demonstrated that cancer immunotherapeutics constitute a clinically effective, marketable drug concept. Ipilimumab is an antagonist immunostimulatory antibody (IS-Ab) that removes the restraint on the immune response by blocking inhibitory receptors on immune cells. Potent immunity can also be elicited by means of agonist IS-Abs that engage activatory receptors. Our program will translate the agonist IS-Ab concept into clinical treatments. This is critical, because a repertoire of complementary drugs that act at different points in the immune regulatory network will be required to counter immune failure in different cancer (sub-)types. Our initiative is supported by longstanding experience as well as by the availability of clinical lead Abs. Pivotal are two clinical trials in which cancer type and treatment regimen have been selected to approximate pre-clinical settings in which striking therapeutic impact with agonist IS-Abs has been obtained. These studies will involve extensive analysis of efficacy-related biomarkers by means of validated assays, not only in blood samples, but also in the most relevant compartment: the tumor microenvironment. While our state-of-the-art agonist IS-Abs are being tested in the clinic, a parallel SME-driven effort will aim at the development of 2nd generation agonist IS-Abs with superior therapeutic index. This innovation is supported by proprietary technology and will result in intellectual property and marketable drugs. Taken together, our interdisciplinary platform is designed to yield maximal benefit for health care, academia and health-related industries in Europe.

Keywords: cancer immunotherapy,antibody-based drugs,agonist immunostimulatory antibody,cd40,ox40,4-1bb,vaccine,pancreatic cancer,chemotherapy,head and neck cancer,human papillomavirus,pd-biomarker
Anti-tick Vaccines to Prevent Tick-borne Diseases in Europe (ANTIDOTE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,Czechia,Germany,Spain,Germany,Netherlands,Slovakia
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-12-01
End date: 2018-11-30
Duration (months): 60.0
Total project cost (EUR): 3823805.0
EU funding (EUR): 2999785.0
Participants: 8
Project status: CLOSED

Background Ixodes ricinus transmits bacterial, protozoal and viral pathogens that cause Lyme borreliosis, babesiosis and tick-borne encephalitis respectively and exceedingly affect Central and Eastern Europe (CEE). During feeding, ticks introduce salivary proteins in the skin that interfere with host defense mechanisms. However, in animals repeated tick infestations as well as vaccination against selected tick proteins can lead to decreased pathogen transmission by inhibiting tick feeding - known as ‘tick immunity’ - or by neutralizing tick proteins that facilitate the transmission of tick-borne pathogens (TBPs). Also humans with hypersensitivity to tick-bites have a lower risk of contracting tick-borne diseases (TBDs). Therefore, anti-tick vaccines encompass an innovative strategy to prevent TBDs in humans, or animals and wildlife to indirectly reduce the risk of contracting TBDs for humans. Overall Objective To identify and characterize tick proteins involved in ‘tick immunity’ and TBP transmission and to use this knowledge to develop anti-tick vaccines to prevent multiple human TBDs. Methods Using state of the art proteomic and transcriptomic approaches we will identify and characterize novel tick salivary gland proteins, which will be subsequently assessed as anti-tick vaccines to protect against LB, babesiosis and TBE in animal models. In addition, through an integrated and multidisciplinary approach involving CEE public health institutes, health organizations and industrial companies we will examine how to develop anti-tick vaccines and implement these in public health systems. Impact ANTIDotE will deliver 1) essential knowledge on the biological mechanisms involved in the pathogenesis of TBDs, 2) proof of concept of an anti-tick vaccine protecting against multiple human TBPs and 3) plans for exploitation and implementation of anti-tick vaccines, significantly contributing to downscaling the severe medical and economic burden that TBDs have on societies.

Keywords: anti-tick vaccines,tick feeding,tick immunity,pathogenesis of tick-borne diseases,lyme borreliosis,tick-borne encephalitis,babesiosis,prevention,cee,health systems.
PROBING THE ROLE OF SODIUM CHANNELS IN PAINFUL NEUROPATHIES (PROPANE STUDY)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Italy,Netherlands,United States,United Kingdom,France,Germany,United Kingdom
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-10-01
End date: 2016-09-30
Duration (months): 36.0
Total project cost (EUR): 6398300.14
EU funding (EUR): 4845089.0
Participants: 9
Project status: CLOSED

Neuropathic pain is a frequent feature of peripheral neuropathy adversely impacting patients’ quality of life and increasing health care costs. Not all individuals with neuropathy develop pain and it is not possible to predict who is more or less susceptible among those with similar risk exposure. Inability to identify high-risk individuals and drug-responder patients and lack of drugs acting on target sites for which there is strong evidence of pathogenicity explain the disappointing effect of current treatments. The PROPANE STUDY aims to address these issues through a solid clinical and genetic approach employing an innovative technological platform. The main objectives are to resolve the genetic architecture of painful neuropathy achieving a stratification of high-risk neuropathic pain patients by novel biomarkers, to deepen understanding of underlying mechanisms and druggable targets and to identify new molecules tailored to potentially drug-responder patients and determine their effects in pre-clinical settings. Results will advance the field beyond the current state-of-the-art opening a window upon a validated individualized pain medicine and having an innovative impact both on patients’ care and market applications. These aims will be achieved by a complementary approach based on targeted sequencing of the 5 sodium channel genes expressed in the nociceptive pathway and identification of new targets by unbiased whole exome sequencing and transcriptome assay. Melding of these two approaches offers a close-to-optimal balance between highly-focused, challenging but clearly achievable goals (sodium channels in pain) and a broader unbiased approach that will capture and deliver other targets and approaches from our unique patient population. Our strong preliminary findings were the departure point of the PROPANE STUDY and the expected results could be translated into solutions able to benefit a large population of pain patients in terms of diagnosis and treatment.

Keywords: neuropathic pain,painful neuropathy,sodium channels,whole exome sequencing,transcriptome,mutations,variants,polymorphisms
European stem cell consortium for neural cell replacement, reprogramming and functional brain repair (NEUROSTEMCELLREPAIR)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Italy,Sweden,Germany,Sweden,United Kingdom,United Kingdom,Italy,United Kingdom,Germany,United Kingdom,Germany
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-10-01
End date: 2017-09-30
Duration (months): 48.0
Total project cost (EUR): 8186684.46
EU funding (EUR): 6000000.0
Participants: 13
Project status: CLOSED

Neurostemcellrepair aims at taking human stem cells through the final steps toward clinical application in cell replacement therapy for neurological disorders. PD will be taken as the prototypical disease because stem cell therapy is now close to clinical translation. Moreover, we will tackle next generation issues pertaining to stem cells at a basic level and develop new approaches and novel cell sources, validated at pre-clinical stages, for both PD and HD. The project teams represent a wide range of competences, including stem cell specialists, developmental neurobiologists, experts in neurodegeneration, scientists with links to the clinic and stem cell manufacturing/clinical validation. The research plan is constructed on exchange of tools, sharing of protocols and expertise and joint deliverables among the participants. We will address issues related to the control of progenitor proliferation and differentiation into authentic, functional and phenotypically stable dopaminergic or striatal neurons, and exploit new technology for cell reprogramming. We will develop strategies to obtain endurable donor cell engraftment in the host, including acquisition of specific neuronal identities and functional integration in the recipient brain. The therapeutic effect will be evaluated following transplantation in animal models of PD and HD. Cutting edge technologies will be guaranteed by the involvement of three SMEs, one industry and partners experienced in bioengineering, who will collectively provide a toolbox to deliver ontogenetic and reprogramming factors, small molecules and miRNA, immunoseparation strategies, in vivo monitoring of donor cell behaviour, scale up and GMP-compliant protocols. Ultimately, Neurostemcellrepair is expected to develop new cell sources based on cellular reprogramming, make significant advance towards stem cell therapy in HD, and close the gap between development and clinical implementation of stem cell replacement therapies for PD.

Keywords: parkinson's disease,huntington's disease,regenerative medicine,pluripotent stem cells,graft differentiation,clinical use,integration of transplanted neurons,functional recovery
Closed-loop Molecular Environment for Minimally Invasive Treatment of Patients with metastatic Gastrointestinal Stromal Tumours (MITIGATE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Germany,Austria,Austria,Italy,Germany,France,France,Germany,Italy,Germany
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-10-01
End date: 2017-09-30
Duration (months): 48.0
Total project cost (EUR): 5864741.13
EU funding (EUR): 4494253.0
Participants: 10
Project status: CLOSED

Gastrointestinal stromal tumours (GIST) are a rare disease that metastasises in up to 85% of patients with subsequent median progression-free survival (PFS) of only around 30 months. Tumours are characterised by activating mutations in the KIT or the PDGFRA gene and therefore treatment is mainly based on tyrosine kinase inhibitors designed to block these mutated receptors. However, drug resistance is often based on mutations changing the conformity of the receptor, leaving little effective therapeutic options to these patients. To date, second line chemotherapy offers a median PFS of 6-9 months and external beam radiotherapy is limited by organs at risk close to the tumour. Alternative approaches such as endoradiotherapy or minimally-invasive ablation techniques are effective for local control but are inconsistently used and are not tailored to the individual patient's type of disease. To address these issues, we propose a closed-loop personalised treatment concept combining endoscopic-assisted tissue sampling, inline biotechnology and targeted molecular PET imaging probe development combined with minimally-invasive treatment monitored by new functional and metabolic MR imaging techniques. A consistent value chain across European academic centres, research institutes and SMEs will be established for mass spectrometry of tumours, linkage of radiochemical molecular imaging probes, design of new immunocompromised animal models and targeted therapeutic radiopharmaceuticals. This closed-loop platform will minimise fragmentation of treatment approaches by a coherent molecular-based multimodality concept, thus providing new treatment options. On a larger scale, the MITIGATE platform can be expanded to further patient cohorts with oligometastatic diseases such as other sarcomas or renal cell carcinoma. For SMEs the access to new animal models and ligands along with translation into clinical practice will strengthen their market share for new probes and imaging technology.

Keywords: gastrointestinal stromal tumours,drug resistance,molecular imaging,targeted radiopharmaceuticals,personalised therapy,minimally-invasive intervention
Neurobiology and Treatment of Adolescent Female Conduct Disorder: The Central Role of Emotion Processing (FEMNAT-CD)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Germany,Netherlands,United Kingdom,Switzerland,Germany,United Kingdom,Ireland,Germany,Spain,Hungary,Greece,Germany,Germany,Spain,Germany,Germany
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-09-01
End date: 2018-02-28
Duration (months): 54.0
Total project cost (EUR): 8058960.06
EU funding (EUR): 5999241.0
Participants: 21
Project status: CLOSED

Conduct Disorder (CD) and Oppositional Defiant Disorder with symptoms of Conduct Disorder (which is included among the abbreviation “CD” throughout the proposal) has a highly negative impact for the affected individual as well as for families and society. Although the number of females exhibiting serious aggressive behaviours is growing, the majority of studies on aetiology and treatment of CD have focused on male subjects only, despite strong evidence for a differential neurobiological basis of female CD. The key aims of the FemNAT-CD consortium are to identify biomarkers and to study disease mechanisms from pre- to postpubertal female CD as well as new psychological and pharmacological treatment options for female adolescent CD targeting emotion processing abilities. With the present proposal, we aim at clarifying the phenomenology and neurobiology of female CD from pre-puberty to post-puberty. We will study the role of genetic and environmental risk factors on female CD, related psychopathology, brain structure and function, HPA axis and autonomic nervous system (ANS) disturbance to elicit CD specific endophenotypes and its biomarkers. We will describe the clinical, neuronal and neurocognitive phenotype of female CD from pre- to postpuberty and related neuroendocrine and ANS function as well as moderating, mediating and direct risk factors to identify distinct homogeneous subtypes to guide targeted future treatment approaches. We translate knowledge of neuropsychological and neurobiological characteristics into targeted intervention by performing a randomised controlled trial of an innovative 16-week DBT-CD-A psychological treatment program focussing on emotion processing. The effect oxytocin and serotonin on neural function underlying emotion processing and aggression will be studied in a female animal model and two proof of concept pharmaco-challenge studies. We also target several societal and education objectives. Our consortium brings together strong clinical and basic science expertise on paediatric CD, including a number of SMEs and a professional management company.

Keywords: conduct disorder,female,emotion processing,genes,environment,neural function,neuroendocrinology
Neuroimaging platform for characterisation of metabolic co-morbidities in psychotic disorders (METSY)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Denmark,Germany,Spain,Finland,Germany,United Kingdom
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-09-01
End date: 2018-02-28
Duration (months): 54.0
Total project cost (EUR): 6085443.81
EU funding (EUR): 4233869.0
Participants: 11
Project status: CLOSED

The theme of this collaborative project is development and application of neuroimaging and bioinformatics tools to study lipid metabolism as a common pathogenic link between psychotic disorders and its metabolic co-morbidities. The overall objective is to identify, prioritize and evaluate multi-modal blood and neuroimaging markers with diagnostic potential for prediction and monitoring of psychotic disorders and associated metabolic co-morbidities. We aim to (1) optimise a multidisciplinary approach for combining positron emission tomography (PET) and magnetic resonance imaging (MRI) with metabolomics approaches, (2) develop a PET-method for exploring endocannabinoid pathways in early psychosis in longitudinal study setting, and (3) develop combined PET-MRI biomarker methodology for psychiatric disorders by studying neurotransmitter interactions with multiple PET scan and MRI sequences. The balance of two or more neurotransmitter systems may function as a novel biomarker in these disorders. The expected impacts are (1) etiopathogenic understanding, (2) new validated multi-modal markers for early disease detection and monitoring, (3) new tools for the identification of subjects who may benefit from specific treatment (4) discovery of new avenues for disease prevention and therapy, and (5) new tools and processes for applying brain imaging in personalised medicine. The consortium brings together clinicians, researchers and industry partners in the domains of psychiatry, neuroimaging, metabolic research, systems biology and bioinformatics.

Keywords: positron emission tomography,magnetic resonance imaging,systems biology,metabolomics,lipid metabolism,endocannabinoids,obesity,psychosis,schizophrenia
BIOIMAGE-Neuromuscular Diseases (BIOIMAGE-NMD)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: United Kingdom,Netherlands,France,Italy,Belgium,United Kingdom,Belgium
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-10-01
End date: 2017-03-31
Duration (months): 42.0
Total project cost (EUR): 7871568.71
EU funding (EUR): 5960532.99
Participants: 9
Project status: CLOSED

BIOIMAGE-NMD will develop and apply imaging technology to monitor response to novel therapies in neuromuscular diseases (NMD) and will use Duchenne muscular dystrophy (DMD) as an exemplar disease. DMD is well characterised genetically and clinically but to date a disease modifying treatment is not available. One of the most promising developments for future treatment of NMD is RNA modulation through antisense oligonucleotides (AON). In DMD, AON are used for exon skipping and this is a genuine example of personalised medicine, where patients are treated according to their specific gene mutation. Quantitative Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopic Imaging (MRSI) are used to assess structural and metabolic muscle pathology in NMD but their effectiveness in monitoring therapy is yet to be shown. The project will apply a simultaneous MRI/MRSI protocol in multi-centre clinical trials of AON therapy in DMD with the aim of establishing a clinical proof of principle that these imaging measures are effective biomarkers of therapeutic response. To enhance the imaging protocol, novel Diffusion Tensor MRI (DTI) methods will be developed and optimised to assess muscle microstructure and applied in these trials. The project will also develop methods for radiolabelling of AON and demonstrate the use of pre-clinical Positron Emission Tomography (PET)/MRI to assess the tissue targeting, bio-distribution and pharmacokinetics of AON in vivo. BIOIMAGE-NMD will deliver PET/MRI and MRI/MRSI technologies for both drug development and clinical evaluation roles which will significantly contribute to bringing personalized therapeutic interventions in rare and common diseases to the market.

Keywords: magnetic resonance imaging,magnetic resonance spectroscopy imaging,positron emission tomography,rare neuromuscular diseases,duchenne muscular dystrophy,antisense oligonucleotides,exon skipping